C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

AstraZeneca1,500 enrolled

Overview

To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Cardiovascular Risk

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients at high cardiovascular risk according to Framingham or SCORE rates Exclusion Criteria: * Not eligible for lipid or statin therapy * Intolerance to therapy * Patients at low or intermediate CV risk

Locations (26)

Research Site

Baja, Hungary

Research Site

Békéscsaba, Hungary

Outcomes

Primary Outcomes

Percent rate of patients achieving target LDL cholesterol goals

Time frame: On each of the 3 visits performed during the study

Percent rate of patients achieving 50% or more reduction in LDL-cholesterol

Time frame: On each of the 3 visits performed during the study

Secondary Outcomes

Percent rate of patients achieving target secondary (total Ch, triglycerides, HDL Ch) goals

Time frame: On each of the 3 visits performed during the study

Percent rate of compliance among patients in the study

Time frame: On each of the 3 visits performed during the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.